This research report provides information on the state of the science in the comorbidity of substance use disorders with mental illness and physical health conditions.
This is an FDA warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth. Despite these risks, buprenorphine is an important treatment option for opioid use disorder (OUD) and pain, and the benefits of these medicines clearly outweigh the risks.
A Practice Guideline which includes treatment recommendations for patients with substance use disorders, as well as background information and a review of available evidence.
Describes three promising behavioral health models to improve care and access for mental health and substance use disorders, including psychiatric mental health nurses, mobile technology, and using crisis services
Reviews 28 studies about alcohol treatments delivered in primary care settings, finding that trials of naltrexone and disulfiram had positive results, but that more studies are needed to assess the effectiveness of the full scope of alcohol treatment
Provides recommendations to support integrated primary care teams, including behavioral health providers, in adapting to and sustaining virtual team-based care
Describes the landscape of telehealth services and provides considerations for healthcare systems, practices, and providers using telehealth services on offering virtual care during and beyond the COVID-19 pandemic
Discusses a health information technology survey conducted to analyze information as it related to research based on electronic health records (EHR) for substance use disorders, finding heterogeneity within existing EHRs and common use of paper records